DIGITAL-VAULT-SERVICES
17.4.2024 09:01:28 CEST | Business Wire | Press release
Clearstream, Deutsche Börse’s post-trade business, intends to make an investment in Digital Vault Services (DVS), a pioneering fintech offering issuance and safekeeping services for digital bank guarantees and sureties in Europe. The investment is subject to applicable regulatory approvals and finalisation of legal documentation.
The investment enables DVS to further enhance and broaden its offering as a market infrastructure solution for corporates and financial institutions. The mid-term plan will be to integrate DVS’s Guarantee Vault with D7, the digital post-trade platform of Deutsche Börse and its post-trade business Clearstream. This will allow D7 for the first time to expand its digital asset product portfolio to non-securities.
With DVS’s established offering in Europe coupled with Clearstream’s leverage and experience offering market infrastructure solutions and connectivity, both parties seek to bring added value to the trade finance ecosystem of corporates, banks and insurers.
Jens Hachmeister, Head of Issuer Services & New Digital Markets at Clearstream, said: “Digital leadership is a central part of Deutsche Börse Group’s Horizon 2026 strategy. The companies’ shared commitment to market innovation makes DVS a perfect fit for Deutsche Börse and Clearstream. We are convinced that DVS’s innovative approach to digital bank guarantees, combined with D7’s track record in digitising securities and Clearstream’s central role in global financial markets, will drive significant growth and deliver value for our clients and ultimately the entire financial industry.”
Ludger Janssen, Co-CEO of Digital Vault Services, added: “Clearstream has emerged as a strategic ally for DVS, echoing our dedication to streamlining processes and recognizing the transformative potential of digitisation in the financial industry, in particular with regards to guarantee management. With technology as our foundation, together with Clearstream and our central and digital guarantee registry, we foresee a unique end-to-end solution that disrupts and modernises outdated procedures with unparalleled efficiency.”
Jaime Gimeno, Co-CEO of Digital Vault Services, added: “Back in 2018, when designing a solution to the cumbersome paper-based process for issuing and storing guarantees, we took inspiration from the central securities depository model used in the securities industry. This strategic partnership with Clearstream now represents a major milestone in our growth journey towards becoming the recognized market infrastructure solution for guarantees in Europe. As we move forward the partnership also positions DVS for exciting new use cases and instruments.”
The investment will be done in exchange for a minority stake and is expected to be completed in H2/2024, subject to applicable regulatory approvals and finalisation of legal documentation.
Digitising financial markets
Today’s financial markets are highly fragmented with isolated technology solutions, resulting in slow processes, high error rates and costs for all market participants. Digital solutions aim to counter these problems by connecting networks and market players across system boundaries, thereby boosting transparency, process efficiency and technology interoperability.
Deutsche Börse and its post-trade business Clearstream provide with their digital post-trade platform D7 a fully digital alternative to conventional physical issuance and managing of financial securities, reducing the time-to-market for securities from days to minutes.
With its Guarantee Vaults product, DVS provides a digital solution allowing corporates to centrally issue and store bank guarantees that are required across different segments as industry standard.
[Editorial note: Please find here a high-resolution photo of Jens Hachmeister.]
About Clearstream
Clearstream is the innovative and trusted post-trade business for the global markets. It runs the leading securities and funds servicing ecosystems of tomorrow. The company operates the German and Luxembourg central securities depositories and an international central securities depository for the Eurobonds market. With 18 trillion Euros in assets under custody, it is one of the world’s largest settlement and custody firms for domestic and international securities.
It also delivers premier fund execution, distribution, data and reporting services, covering over 55 fund markets worldwide. Clearstream is part of Deutsche Börse Group, an international exchange organisation and provider of innovative market infrastructures.
To learn more, visit us at www.clearstream.com or connect via LinkedIn.
About Digital Vault Services
The idea for Digital Vault Services emerged in 2017 from the needs of the Treasury department of Lindner Group KG, Arnstorf, Germany. A strong working group of corporates and financial institutions from across Europe then came together to design a market solution to a common problem around the paper-based guarantee process. Since then, Digital Vault Services has rapidly evolved, gaining strong traction in DACH and now expanding into other European markets including the Nordics. Headquartered in Munich, Germany, Digital Vault Services is at the forefront of guarantee digitisation. The current shareholders, being Lindner Group KG and Management, now welcome Deutsche Börse to join them on the exciting journey ahead.
Visit us at www.digitalvaultservices.com or connect via LinkedIn to get to know more about Digital Vault Services and Guarantee Vault.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240417214758/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom